Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | KIT positive |
Gene Variant Detail | |
Relevant Treatment Approaches | KIT Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
KIT positive | breast cancer | predicted - sensitive | KIT Inhibitor | Imatinib + Letrozole | Phase 0 | Actionable | In a pilot trial, Gleevec (imatinib mesylate) and Femara (letrozole) combination treatment resulted in clinical partial response in 90% (9/10) and stable disease in 10% (1/10) of the evaluable patients with invasive hormone-sensitive breast cancer, 8 of the 13 enrolled patients had KIT-positive tumors (PMID: 18248884). | 18248884 |
KIT positive | prostate neuroendocrine neoplasm | no benefit | KIT Inhibitor | Imatinib | Preclinical | Actionable | In a preclinical study, a prostate neuroendocrine tumor mouse model expressing Kit did not respond to Gleevec (imatinib), a result of impaired signaling of the Kit pathway (PMID: 27980106). | 27980106 |
KIT positive | germ cell cancer | resistant | KIT Inhibitor | Imatinib | Phase II | Actionable | In a small Phase II study, 18 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496). | 16462496 |
KIT positive | gastrointestinal stromal tumor | sensitive | KIT Inhibitor | Imatinib | FDA approved | Actionable | In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in an overall response rate of 38% (56/147) and a median duration of response of 13 weeks in patients with metastatic or unresectable KIT-positive GIST (PMID: 12374669). | 12374669 detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02260505 | Phase III | Imatinib | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist) | Recruiting | FRA | 0 |
NCT02642016 | Phase I | CDX-0158 | A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT00812240 | Phase III | Masitinib Imatinib | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment | Terminated | USA | FRA | 1 |
NCT05009927 | Phase II | Imatinib | Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten) | Recruiting | FRA | 0 |
NCT01222143 | Phase Ib/II | Cytarabine + Etoposide + Mitoxantrone Nilotinib | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | Terminated | CAN | 0 |